Literature DB >> 3166544

Pharmacokinetic, bacteriological and clinical aspects on the use of doxycycline in patients with active duodenal ulcer associated with Campylobacter pylori.

P Unge1, H Gnarpe.   

Abstract

Seven patients with active duodenal ulcer and positive cultures for Campylobacter pylori were given anti-ulcer treatment for 28 days with the addition of doxycycline for the last nine days. Repeated endoscopy with biopsy for culture and doxycycline concentration determinations from the mucosa at the end of doxycycline therapy showed that five of seven patients remained positive in culture. The concentrations of doxycycline in biopsy material were 0.1 to 0.3 mg/kg in four patients; in three patients the level of antibiotic was not measurable. The serum concentrations of doxycycline in six patients varied between 0.5 and 2.7 mg/l. One patient had less than 0.5 mg/l. The two patients with C. pylori negative cultures at the end of therapy had serum concentrations of doxycycline of 2.4 and 1.0 mg/l. These patients were positive in biopsy culture for C. pylori 12 weeks after therapy. In conclusion, doxycycline does not eradicate C. pylori when given in recommended dosage for 9 days.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3166544

Source DB:  PubMed          Journal:  Scand J Infect Dis Suppl        ISSN: 0300-8878


  6 in total

1.  Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.

Authors:  T Iwahi; H Satoh; M Nakao; T Iwasaki; T Yamazaki; K Kubo; T Tamura; A Imada
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Role of metronidazole resistance in therapy of Helicobacter pylori infections.

Authors:  H Rautelin; K Seppälä; O V Renkonen; U Vainio; T U Kosunen
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

3.  Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents against Helicobacter pylori.

Authors:  M Nakao; M Tada; K Tsuchimori; M Uekata
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

4.  Gastric penetration of amoxicillin in a human Helicobacter pylori-infected xenograft model.

Authors:  A Lozniewski; A Duprez; C Renault; F Muhale; M C Conroy; M Weber; A Le Faou; F Jehl
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

5.  Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells.

Authors:  K Nagata; H Satoh; T Iwahi; T Shimoyama; T Tamura
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

6.  Guinea pig model for antibiotic transport across gastric mucosa: inhibitory tissue concentrations of clindamycin against Helicobacter pylori (Campylobacter pylori) following two separate dose regimens.

Authors:  T U Westblom; D E Duriex; E Madan; R B Belshe
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.